WilliamElliotRosenfeldMD

Neurology • Chesterfield, MO

Physician

Join to view full profile

Dr. Rosenfeld is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rosenfeld's full profile

Already have an account?

Office
222 S Woods Mill Rd
Suite 610N
Chesterfield, MO 63017
Phone+1 314-453-9300

Education & Training

University of Miami/Jackson Health SystemResidency, Neurology, 1980 - 1983
University of Miami/Jackson Health SystemInternship, Internal Medicine, 1979 - 1980
Texas Tech University Health Sciences Center School of MedicineClass of 1979

Certifications & Licensure

MO State Medical License 1987 - 2026
MN State Medical License 1984 - 1987
FL State Medical License 1980 - 1985
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013

Clinical Trials

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy Start of enrollment: 2010 Jun 01
Completed
Phase 3
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures Start of enrollment: 2011 Jul 06
Completed
Phase 2
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension Start of enrollment: 2013 Oct 01
Completed
Phase 3

Publications & Presentations

PubMed

3 citations
Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies.
Gregory L Krauss, Steve S Chung, Louis Ferrari, Sean Stern, William E Rosenfeld
Epilepsy & Behavior. 2024-02-01
4 citations
Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
J Eric Piña-Garza, Vicente Villanueva, William Rosenfeld, Harumi Yoshinaga, Anna Patten
Epilepsy & Behavior. 2022-10-01
7 citations
Efficacy of cenobamate by focal seizure subtypes: Post-hoc analysis of a phase 3, multicenter, open-label study.
William E Rosenfeld, Louis Ferrari, Marc Kamin
Epilepsy Research. 2022-07-01

Press Mentions

Latest XCOPRI® (Cenobamate Tablets) CV Post-Hoc Analysis Presented at the 75th American Academy of Neurology Annual MeetingApril 17th, 2023
Epilepsia Publishes Two Post-Hoc Analyses from Long-Term Study of XCOPRI® (Cenobamate Tablets) CVOctober 12th, 2021
Epilepsia Publishes Two Post-Hoc Analyses from Long-Term Study of XCOPRI® (Cenobamate Tablets) CVOctober 12th, 2021
Join now to see all